Johnson & Johnson (JNJ) Tops Q4 EPS by 1c; Guides FY15 EPS
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.27, $0.01 better than the analyst estimate of $1.26. Revenue for the quarter came in at $18.3 billion versus the consensus estimate of $18.59 billion.
"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our Pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our Medical Devices business and are continuing our market leadership with iconic brands in our Consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."
Johnson & Johnson sees FY2015 EPS of $6.12 - $6.27, versus the consensus of $6.13.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.